TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download:
STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of PrLEMTRADA™(alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
LEMTRADA 12 mg has a dosing and administration schedule of two annual treatment courses. The first treatment course of LEMTRADA is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later. LEMTRADA patients require monitoring at regular intervals between treatment courses and for 48 months following the final infusion.
During an extensive, ongoing clinical development program, 80 per cent of RRMS patients who received two treatment courses of LEMTRADA required no further therapy and 55 per cent remained relapse-free through the first year of the extension study. Unlike other current disease modifying therapies in which stopping treatment usually results in resumed disease activity, LEMTRADA continues to have a durable effect far beyond the two annual treatment courses. In fact, in more than 70 per cent of clinical trial patients, disability scores improved or remained stable over three years.
SHOT LIST: Interview with Dr. Mark Freedman, Director, Multiple Sclerosis Research Unit, Professor of Neurology and Senior Scientist at the University of Ottawa and Ottawa Hospital Research Institute B-roll: Dr. Freedman with patient, LEMTRADA product shot, LEMTRADA animation
WEB Video Preview and Download link:
TIME OF POSTING: 8:00 a.m. ET
DATE OF POSTING: February 27, 2014
All video can be viewed by clicking on the link. Broadcast quality video is available for download by accredited journalists. Please contact [email protected] for access.
STATIONS, FOR FURTHER INFORMATION, PLEASE CALL:
Account Coordinator, Cohn & Wolfe
For assistance with Video On-Demand, please contact CNW at [email protected] or (416) 863-5612.
CNW Video On-Demand http://cnw.pathfireondemand.com provides free, secure and easy-to-use broadcast quality material direct from our website to accredited journalists worldwide.
This material is offered for free and unrestricted news use.
CNW VIDEO SERVICES.
Video with caption: "Video: B-Roll: LEMTRADA now available for Canadians living with RRMS. Video with Dr. Mark Freedman, Director, MS Research Unit, Professor of Neurology and Senior Scientist, University of Ottawa and Ottawa Hospital Research Institute, as well as investigator, LEMTRADA clinical trial program.". Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20140227_C7808_VIDEO_EN_37222.mp4&posterurl=http://photos.newswire.ca/images/20140227_C7808_PHOTO_EN_37222.jpg&clientName=Genzyme&caption=Video%3A%20B%2DRoll%3A%20LEMTRADA%20now%20available%20for%20Canadians%20living%20with%20RRMS%2E%20Video%20with%20Dr%2E%20Mark%20Freedman%2C%20Director%2C%20MS%20Research%20Unit%2C%20Professor%20of%20Neurology%20and%20Senior%20Scientist%2C%20University%20of%20Ottawa%20and%20Ottawa%20Hospital%20Research%20Institute%2C%20as%20well%20as%20investigator%2C%20LEMTRADA%20clinical%20trial%20program%2E&title=GENZYME%20%2D%20Video%20B%2DRoll%20available%20via%20CNW%20%2D%20First%2Dof%2DIts%2DKind%20Treatment%20for%20Relapsing%2DRemitting%20Multiple%20Sclerosis%20Now%20Available%20in%20Canada&headline=Video%20B%2DRoll%20available%20via%20CNW%20%2D%20First%2Dof%2DIts%2DKind%20Treatment%20for%20Relapsing%2DRemitting%20Multiple%20Sclerosis%20Now%20Available%20in%20Canada
For further information:
CNW VIDEO SERVICES, TORONTO (416) 863-5612